Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data

Table 2 Relationships of Beclin1, LC3, and 4E-BP1 with short-term efficacy of first-line cetuximab-containing therapy in 25 patients with wild-type KRAS

Factor			DCR		ORR		PFS
		n (%)	n (%)	P-value	n (%)	P-value	Time (mo)	P-value
		25
Beclin1	High	12 (48.0)	7 (58.3)	0.325	5 (41.6)	1.000	8.80	0.843
	Low	8 (32.0)	7 (87.5)		4 (50.0)		4.70
	NA	5 (20.0)
LC3	High	12 (48.0)	7 (58.3)	0.325	4 (33.3)	0.362	4.70	0.167
	Low	8 (32.0)	7 (87.5)		5 (62.5)		9.96
	NA	5 (20.0)
4E-BP1	High	15 (60.0)	12 (80.0)	0.560	9 (60.0)	0.303	5.32	0.410
	Low	5 (20.0)	3 (60.0)		1 (20.0)		7.36
	NA	5 (20.0)

LC3: Microtubule-associated protein 1A/B-light chain 3; 4E-BP1: 4E-binding protein 1; NA: Not applicable; DCR: Disease control rate; ORR: Overall response rate; PFS: Primary-progression-free survival from the initiation of first-line treatment to tumor progression, death from any cause, or the last follow-up.